Product Name: Pituitary growth hormone
Molecular Formula: Unspecified
CAS NO: 9002-72-6
Classification Code of Pituitary growth hormone (CAS NO.9002-72-6): Hormone ; Human Data ; Mutation data ; Natural Product ; Reproductive Effect ; Tumor data 
Storage Temp: 2-8°C
Form: lyophilized powder

 The identification, purification and later synthesis of Pituitary growth hormone (CAS NO.9002-72-6) is associated with Choh Hao Li. Genentech pioneered the first use of recombinant human growth hormone for human therapy in 1981.
 Prior to its production by recombinant DNA technology, growth hormone used to treat deficiencies was extracted from the pituitary glands of cadavers. Attempts to create a wholly synthetic HGH failed. Limited supplies of HGH resulted in the restriction of HGH therapy to the treatment of idiopathic short stature. Furthermore, growth hormone from other primates was found to be inactive in humans.
 In 1985, unusual cases of Creutzfeldt-Jacob disease were found in individuals that had received cadaver-derived HGH ten to fifteen years previously. Based on the assumption that infectious prions causing the disease were transferred along with the cadaver-derived HGH, cadaver-derived HGH was removed from the market.
In 1985, biosynthetic human growth hormone replaced pituitary-derived human growth hormone for therapeutic use in the U.S. and elsewhere.As of 2005, recombinant growth hormones available in the United States (and their manufacturers) included Nutropin (Genentech), Humatrope (Lilly), Genotropin (Pfizer), Norditropin (Novo), and Saizen (Merck Serono). In 2006, the U.S. Food and Drug Association (FDA) approved a version of rhGH called Omnitrope (Sandoz). A sustained-release form of growth hormone, Nutropin Depot (Genentech and Alkermes) was approved by the FDA in 1999, allowing for fewer injections (every 2 or 4 weeks instead of daily); however, the product was discontinued in 2004.

Questionable carcinogen with experimental carcinogenic data. Experimental teratogenic and reproductive effects. Mutation data reported.
Safety Information of Pituitary growth hormone (CAS NO.9002-72-6):
Hazard Codes: B
WGK Germany: 3
RTECS: TO7385000

 Pituitary growth hormone , with CAS number of 9002-72-6, can be called adenohypophysealgrowthhormone ; hormonesomatotrope ; anteriorpituitarygrowthhormone ; hypophysealgrowthhormone ; phyol ; phyone ; pituitarygrowthhormone ; somacton . 
  Pituitary growth hormone (CAS NO.9002-72-6) can be used to treat conditions that produce short stature but are not related to deficiencies. However, results are not as dramatic when compared to short stature that is solely due to deficiency of GH. Examples of other causes of shortness often treated with Somatotropin are Turner syndrome, chronic renal failure, Prader-Willi syndrome, intrauterine growth retardation, and severe idiopathic short stature. Higher pharmacologic doses are required to produce significant acceleration of growth in these conditions, producing blood levels well above normal.
 Despite the higher doses, side-effects during treatment are rare, and vary little according to the condition being treated. Somatotropin treatment improves muscle strength and slightly reduces body fat in Prader-Willi syndrome, which are significant concerns beyond the need to increase height. Somatotropin is also useful in maintaining muscle mass in wasting due to AIDS. Somatotropin can also be used in patients with short bowel syndrome to lessen the requirement for intravenous total parenteral nutrition. Somatotropin can also be used for conditions that do not cause short stature. Typically, growth hormone treatment for conditions unrelated to stature is controversial and experimental. Somatotropin has been used for remission of multiple sclerosis, to reverse the effects of aging in older adults (see below), to enhance weight loss in obesity, as well as fibromyalgia, heart failure, Crohn's disease and ulcerative colitis, burns and bodybuilding or athletic enhancement.